Osteosarcoma

ClinicalAugust 15, 2026

Phase II/III Trial of Cabozantinib with Chemotherapy in Newly Diagnosed Osteosarcoma

The National Cancer Institute is conducting a phase II/III trial to evaluate cabozantinib combined with standard chemotherapy in patients with newly diagnosed osteosarcoma.

Companies

Assets

Recent signals(5)

Phase II/III Trial of Cabozantinib with Chemotherapy in Newly Diagnosed Osteosarcoma

Exploring m(6)A Modification as Therapeutic Target in Osteosarcoma

KIBRA identified as a tumor suppressor in osteosarcoma via Wnt/β-catenin inhibition

Ruthenium-based metallodrug shows promise against cisplatin-resistant osteosarcoma

KIF18A Inhibitor Shows Promise Against Osteosarcoma Growth

Upcoming catalysts

Indications

Get signals before the market moves